title: [Effect of telbivudine on infants born to HBsAg-positive mothers with non-/hypo-response to hepatitis B vaccine during their second and third trimesters of pregnancy].
abstract: Objective:To explore the effect of telbivudine treatment in a prevention program on infants born to HBsAg-positive mothers with non-/hypo-responsiveness to hepatitis B vaccine.Methods:A retrospective cohort study with a total of 321 HBsAg-positive pregnant women and their infants enrolled, was conducted. The mothers were recruited from the Third People' s Hospital of Taiyuan, from July 2011 to January 2013. According to the situation of telbivudine intake in second and third trimesters of pregnancy, the participants were divided into two groups: with telbivudine-treated or as control. The neonates were followed up till the age of 12 months. Maternal, neonatal and infantile HBV-M together with HBV DNA in serum were measured using the electro-chemiluminescence immuno-assay (ECLIA) kits and fluorescence quantitative polymerase chain reaction (FQ-PCR) assay, respectively.Results:The rate of non-/hypo-response was 17.99%. After adjusting the potential confounding factors, the telbivudine treatment on HBsAg-positive mothers in the second and third trimesters of pregnancy seemed as the protective factor for non-/hypo-response to hepatitis B vaccine in infants (aRR=0.119, 95% CI: 0.014-0.974). Levels of IFN-γ and IL-10 in telbivudine-treated group were higher than those in the controls (aRR=8.684, 95%CI: 1.977-38.140; aRR=5.330, 95% CI: 1.278-22.236). When the serum levels of IFN-γ and IL-10 in neonatal peripheral blood were higher than 228.47 pg/ml and 174.05 pg/ml respectively, the infants were less likely to be non-/hypo-responsive to the hepatitis B vaccine (aRR=0.300, 95%CI: 0.105-0.857) (aRR= 0.104, 95% CI: 0.030-0.354).Conclusion:Telbivudine treatment provided for the HBsAg-positive mothers in second and third trimesters of pregnancy were less likely to develop non-/low-responsive to hepatitis B vaccine in infants since IFN-γ and IL-10 might have played a vital role in this process.
authors.affiliation: Department of Epidemiology, Shanxi Medical University, Taiyuan 030001, China.
authors.forename: X X
authors.initials: XX
authors.lastname: Xu
authors.affiliation: Department of Obstetrics and Gynecology, the Third People's Hospital of Taiyuan, Taiyuan 030001, China.
authors.forename: B
authors.initials: B
authors.lastname: Wang
authors.affiliation: Department of Epidemiology, Shanxi Medical University, Taiyuan 030001, China.
authors.forename: X F
authors.initials: XF
authors.lastname: Wang
authors.affiliation: Department of Epidemiology, Shanxi Medical University, Taiyuan 030001, China.
authors.forename: H X
authors.initials: HX
authors.lastname: Wen
authors.affiliation: Department of Epidemiology, Shanxi Medical University, Taiyuan 030001, China.
authors.forename: F
authors.initials: F
authors.lastname: Zhang
authors.affiliation: Department of Epidemiology, Shanxi Medical University, Taiyuan 030001, China.
authors.forename: Z Q
authors.initials: ZQ
authors.lastname: Yang
authors.affiliation: Department of Epidemiology, Shanxi Medical University, Taiyuan 030001, China.
authors.forename: H Y
authors.initials: HY
authors.lastname: Hao
authors.affiliation: Department of Epidemiology, Shanxi Medical University, Taiyuan 030001, China.
authors.forename: T
authors.initials: T
authors.lastname: Wang
authors.affiliation: Department of Epidemiology, Shanxi Medical University, Taiyuan 030001, China.
authors.forename: X H
authors.initials: XH
authors.lastname: Shi
authors.affiliation: Department of Epidemiology, Shanxi Medical University, Taiyuan 030001, China.
authors.forename: Z D
authors.initials: ZD
authors.lastname: Fu
authors.affiliation: Department of Epidemiology, Shanxi Medical University, Taiyuan 030001, China.
authors.forename: B
authors.initials: B
authors.lastname: Wang
authors.affiliation: Department of Epidemiology, Shanxi Medical University, Taiyuan 030001, China.
authors.forename: S P
authors.initials: SP
authors.lastname: Wang
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood*; D002681:China; D004279:DNA, Viral / Q000097:blood; D005260:Female; D006509:Hepatitis B / Q000097:blood / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control; D006510:Hepatitis B Antibodies / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D006515:Hepatitis B virus / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007371:Interferon-gamma / Q000097:blood; D016753:Interleukin-10 / Q000097:blood; D008163:Luminescent Measurements / Q000379:methods*; D009035:Mothers; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D011263:Pregnancy Trimester, Third; D012189:Retrospective Studies; D000077712:Telbivudine; D013936:Thymidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D004279:DNA, Viral; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D016753:Interleukin-10; D000077712:Telbivudine; D007371:Interferon-gamma; D013936:Thymidine
keywords: Hepatitis B vaccine; Interferon-γ; Interleukin-10; Non-/hypo-response; Telbivudine